



Contents lists available at ScienceDirect

## Advanced Drug Delivery Reviews

journal homepage: [www.elsevier.com/locate/addr](http://www.elsevier.com/locate/addr)

## Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies<sup>☆</sup>

Olivier Keunen<sup>a,b,\*</sup>, Torfinn Taxt<sup>b,c</sup>, Renate Grüner<sup>c</sup>, Morten Lund-Johansen<sup>d,e</sup>, Joerg-Christian Tonn<sup>f</sup>, Tina Pavlin<sup>g</sup>, Rolf Bjerkvig<sup>a,b,h</sup>, Simone P. Niclou<sup>a,\*\*</sup>, Frits Thorsen<sup>b,g,h</sup>

<sup>a</sup> NorLux Neuro-Oncology Laboratory, Department of Oncology, Centre de Recherche Public de la Santé, Luxembourg, Luxembourg

<sup>b</sup> Translational Cancer Research, Department of Biomedicine, University of Bergen, Norway

<sup>c</sup> Department of Radiology, Haukeland University Hospital, Bergen, Norway

<sup>d</sup> Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway

<sup>e</sup> Department of Clinical Medicine, University of Bergen, Norway

<sup>f</sup> Department of Nuclear Medicine, University of Munich, Munich, Germany

<sup>g</sup> Molecular Imaging Center, Department of Biomedicine, University of Bergen, Norway

<sup>h</sup> The Kristian Gerhard Jebsen Brain Tumour Research Center, Department of Biomedicine, University of Bergen, Norway

## ARTICLE INFO

## Article history:

Accepted 22 July 2014

Available online xxx

## Chemical compounds studied in this article:

Temozolomide (PubChem CID: 5394)

Gadolinium (PubChem CID: 23982)

<sup>11</sup>C-methionine (PubChem CID: 15556483)<sup>18</sup>F-fluoroethyltyrosine (PubChem CID: 44439370)<sup>18</sup>F-fluorodeoxyglucose (PubChem CID: 450503)<sup>18</sup>F-fluorothymidine (PubChem CID: 450772)<sup>18</sup>F-fluoromisonidazole (PubChem CID: 450173)

## Keywords:

Brain tumors

Neuroimaging

Magnetic resonance imaging

Positron emission tomography

Molecular imaging

Computer vision

Image analysis

Radiology information systems

## ABSTRACT

The vast majority of malignant gliomas relapse after surgery and standard radio-chemotherapy. Novel molecular and cellular therapies are thus being developed, targeting specific aspects of tumor growth. While histopathology remains the gold standard for tumor classification, neuroimaging has over the years taken a central role in the diagnosis and treatment follow up of brain tumors. It is used to detect and localize lesions, define the target area for biopsies, plan surgical and radiation interventions and assess tumor progression and treatment outcome. In recent years the application of novel drugs including anti-angiogenic agents that affect the tumor vasculature, has drastically modulated the outcome of brain tumor imaging. To properly evaluate the effects of emerging experimental therapies and successfully support treatment decisions, neuroimaging will have to evolve. Multimodal imaging systems with existing and new contrast agents, molecular tracers, technological advances and advanced data analysis can all contribute to the establishment of disease relevant biomarkers that will improve disease management and patient care. In this review, we address the challenges of glioma imaging in the context of novel molecular and cellular therapies, and take a prospective look at emerging experimental and pre-clinical imaging techniques that bear the promise of meeting these challenges.

© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

## Contents

1. Introduction . . . . .	0
2. Imaging of gliomas in the clinic . . . . .	0
2.1. MRI . . . . .	0

<sup>☆</sup> This review is part of the *Advanced Drug Delivery Reviews* theme issue on “Targeted Imaging”.

\* Correspondence to: O. Keunen, Norlux Neuro-Oncology Laboratory, CRP Santé, 84, Val Fleuri, L-1586 Luxembourg, Luxembourg. Tel.: +352 26970 833.

\*\* Correspondence to: S. Niclou, Norlux Neuro-Oncology Laboratory, CRP Santé, 84, Val Fleuri, L-1586 Luxembourg, Luxembourg. Tel.: +352 26970 273.

E-mail addresses: [olivier.keunen@crp-sante.lu](mailto:olivier.keunen@crp-sante.lu) (O. Keunen), [simone.niclou@crp-sante.lu](mailto:simone.niclou@crp-sante.lu) (S.P. Niclou).

<http://dx.doi.org/10.1016/j.addr.2014.07.010>

0169-409X/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

Please cite this article as: O. Keunen, et al., Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies, *Adv. Drug Deliv. Rev.* (2014), <http://dx.doi.org/10.1016/j.addr.2014.07.010>

2.2.	PET . . . . .	0
2.3.	Challenges . . . . .	0
3.	Experimental approaches to the imaging of gliomas . . . . .	0
3.1.	MRI contrast strategies . . . . .	0
3.1.1.	Exogenous contrast agents . . . . .	0
3.1.2.	Magnetization transfer . . . . .	0
3.1.3.	Spin tagging . . . . .	0
3.1.4.	Functional MRI . . . . .	0
3.1.5.	Susceptibility weighted imaging . . . . .	0
3.1.6.	Angiography . . . . .	0
3.1.7.	Specific tissue signal suppression . . . . .	0
3.1.8.	Elastography . . . . .	0
3.2.	Advances in physiological imaging . . . . .	0
3.2.1.	Perfusion . . . . .	0
3.2.2.	Diffusion . . . . .	0
3.3.	Advances in magnetic resonance spectroscopy . . . . .	0
3.3.1.	Spectral editing . . . . .	0
3.3.2.	Multinuclear spectroscopy . . . . .	0
3.3.3.	Hyperpolarization . . . . .	0
3.4.	Advances in molecular imaging . . . . .	0
3.4.1.	Proliferation and metabolic activity . . . . .	0
3.4.2.	Cellular death . . . . .	0
3.4.3.	Tumor vasculature . . . . .	0
3.4.4.	Immune response . . . . .	0
3.4.5.	Molecular targets and pathways . . . . .	0
3.4.6.	Drug delivery . . . . .	0
3.4.7.	Other molecular imaging approaches . . . . .	0
4.	Technological advances . . . . .	0
4.1.	Next generation imaging modalities . . . . .	0
4.1.1.	High field magnets . . . . .	0
4.1.2.	Parallel imaging . . . . .	0
4.1.3.	Fast imaging protocols . . . . .	0
4.1.4.	Hybrid systems . . . . .	0
4.2.	Advances in data analysis . . . . .	0
4.2.1.	Quantitative biomarkers . . . . .	0
4.2.2.	Composite biomarkers . . . . .	0
4.2.3.	Computer-assisted decision making . . . . .	0
4.2.4.	Tumor growth modeling . . . . .	0
4.2.5.	Visualization . . . . .	0
4.2.6.	Virtual and augmented reality . . . . .	0
4.2.7.	'Omics' data enrichment . . . . .	0
5.	Perspectives . . . . .	0
	Acknowledgments . . . . .	0
	References . . . . .	0

---

#### Key points

- High grade gliomas are heterogeneous and infiltrative, causing them to relapse after conventional standard therapies. New treatment approaches such as molecular and cellular therapies offer the perspective of a better personalized treatment.
  - To provide clinicians with the appropriate information needed to efficiently deal with the treatment of gliomas, neuroimaging would benefit from an evolution from non-specific contrast based protocols to protocols that are oriented toward disease relevant and treatment specific biomarkers.
  - Technological advances and the combination of imaging modalities, new contrast mechanisms and advanced data processing techniques will assist in addressing the challenges of tumor imaging in the context of emerging treatment approaches.
- 

## 1. Introduction

Gliomas are brain tumors that arise from abnormally proliferating glial cells, which normally provide support and protection of neurons in the central nervous system. Glioblastoma (GBM), the focus of the present review, represents the most malignant form of gliomas with a

mean patient survival after diagnosis of about 14 months [1]. Despite standard treatment involving surgical resection, radiation therapy and chemotherapy, only very few patients survive more than 5 years [2]. GBMs are highly heterogeneous; when tumors in different patients are compared, they vary in mutation status [3], in putative glial cell lineage, in epigenetic profiles and in histological appearance. Similarly, within single tumors, cell clones with different genetic profiles and even different ploidy co-exist within a microenvironment made up of varying non-neoplastic stromal cells, immune cells and extracellular matrix components. This heterogeneity represents a key challenge in tumor characterization and for the development of effective therapies. Data from high throughput molecular analyses attempts to define subclasses of GBM that differ by their genetic and epigenetic alterations, gene expression profiles, clinical aggressiveness, prognosis and response to treatment [4,5]. Although there is some discrepancy in currently proposed subclasses, the most recent work combines methylation profiles with specific genetic mutations and patient age group, to propose a classification into 6 distinct subgroups for pediatric and adult GBM [6]. Yet, these molecular classifications have so far not led to a diversification in treatment [7].

Initial diagnosis of GBM is largely based on magnetic resonance imaging or computed tomography, indicating the importance of

Download English Version:

<https://daneshyari.com/en/article/8403432>

Download Persian Version:

<https://daneshyari.com/article/8403432>

[Daneshyari.com](https://daneshyari.com)